BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2012757)

  • 1. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance.
    Archimbaud E; Bailly M; Doré JF
    Br J Haematol; 1991 Mar; 77(3):328-34. PubMed ID: 2012757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of LAK cells in vitro in patients with acute leukemia.
    Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
    Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphokine-activated killer cytotoxicity against leukaemic blast cells.
    Tratkiewicz JA; Szer J; Boyd RL
    Clin Exp Immunol; 1990 Apr; 80(1):94-9. PubMed ID: 2323104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
    Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF
    Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
    Foa R; Fierro MT; Cesano A; Guarini A; Bonferroni M; Raspadori D; Miniero R; Lauria F; Gavosto F
    Blood; 1991 Aug; 78(4):1041-6. PubMed ID: 1868239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
    Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
    Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
    Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
    Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
    Verfaillie C; Kay N; Miller W; McGlave P
    Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells.
    Notter M; Ludwig WD; Bremer S; Thiel E
    Blood; 1993 Nov; 82(10):3113-24. PubMed ID: 7693036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation are donor-derived.
    Boughton BJ; Simpson AW; Phaure TA; Beatty C
    Cancer Immunol Immunother; 1995 Jul; 41(1):68-70. PubMed ID: 7641221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cells.
    Panayotides P; Porwit A; Sjögren AM; Wasserman J; Reizenstein P
    Eur J Haematol; 1988 Apr; 40(4):362-7. PubMed ID: 3259192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of adherent lymphokine activated killer (A-LAK) cells from patients with acute myelogenous leukaemia.
    Sedlmayr P; Rabinowich H; Winkelstein A; Herberman RB; Whiteside TL
    Br J Cancer; 1992 Feb; 65(2):222-8. PubMed ID: 1739621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
    Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
    Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2 induction of lymphokine-activated killer activity in the peripheral blood of an acute lymphoblastic leukaemia patient--case study.
    Dickinson AM; Lennard AL; Cartner R; Proctor SJ
    Leukemia; 1992 Sep; 6(9):957-60. PubMed ID: 1518307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloblastic leukaemia: graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease.
    Boughton BJ; Simpson AW
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):1-6. PubMed ID: 10390074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
    Hermann GG; Zeuthen J; Claësson MH
    Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells.
    Teichmann JV; Ludwig WD; Thiel E
    Int J Hematol; 1992 Jun; 55(3):255-64. PubMed ID: 1498316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.